Third Rock Launches Ember Therapeutics With Focus On Obesity And Type 2 Diabetes
The sole investor in a $34 million Series A financing, Third Rock hopes Ember can be a pioneer in development of obesity drugs that augment brown fat levels.
The sole investor in a $34 million Series A financing, Third Rock hopes Ember can be a pioneer in development of obesity drugs that augment brown fat levels.